NURO - NeuroMetrix announces sales force expansion for Quell Fibromyalgia
2023-07-11 11:06:07 ET
- NeuroMetrix ( NASDAQ: NURO ) has announced expansion of its sales force to drive further adoption of Quell Fibromyalgia, which is the first and only medical device authorized by the U.S. FDA to help reduce the symptoms of fibromyalgia.
- This expansion follows positive results from the strategic launch of Quell Fibromyalgia in Dec. 2022, and is designed to intensify commercial efforts in the California, Texas and Florida markets.
- We look forward to bringing Quell Fibromyalgia to practices in California, Texas and Florida that seek to offer their patients the latest innovation in fibromyalgia treatments.” said Shai N. Gozani, M.D., Ph.D., CEO.
For further details see:
NeuroMetrix announces sales force expansion for Quell Fibromyalgia